We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI Taps Growing ICI Market With New xM Assay
Read MoreHide Full Article
Key Takeaways
TEM debuts xM for TRM, a liquid biopsy assay to monitor response to ICI therapy in solid tumors.
Tempus AI's xM uses ctDNA and a multi-parametric algorithm to assess molecular response in cancer patients.
TEM expands its precision oncology tools as demand for ICI therapies rises in advanced cancers.
Tempus AI, Inc. (TEM - Free Report) recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus AI’s growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). This innovative offering marks a significant advancement in the precision oncology space, where real-time response monitoring is essential for optimizing cancer treatment.
The rising prevalence of cancers such as lung, breast, bladder, and cervical cancers, as well as melanomas and hodgkin lymphoma, has driven the adoption of immune checkpoint inhibitor therapies as a key component of modern cancer treatment. Per a Grand View Research analysis, the global immune checkpoint inhibitors market size is projected to reach $154.25 billion by 2030, at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2030.
xM for TRM is designed to quantify changes in circulating tumor DNA (ctDNA) longitudinally from a blood sample, enabling early molecular response assessment in patients with advanced cancers receiving ICI alone or combination therapies. xM for TRM leverages a unique multi-parametric algorithm, integrating copy number variations (CNVs), along with somatic and germline variant allele frequencies (“VAFs”), for a comprehensive and robust estimation of circulating tumor fraction.
Recent Development by TEM’s Competitors
In March, Exact Sciences (EXAS - Free Report) launched the Cologuard Plus test, the company’s next-generation colon cancer screening test. The Cologuard Plus test detects cancers and precancerous polyps with even greater sensitivity than the Cologuard test while reducing false positives by nearly 40%. In April, it launched the Oncodetect test, its molecular residual disease and recurrence monitoring test. Furthermore, the company is on track for the launch of Cancerguard EX, a laboratory-developed multi-cancer screening test, in the second half of 2025.
Guardant Health (GH - Free Report) has enhanced its Guardant360 Liquid test by launching nearly a dozen new applications built on its Guardant Infinity multiomic platform and AI engine. Comprehensive biomarker testing through immunohistochemistry (using tumor tissue) has been the standard of care in oncology. The Guardant360 Liquid test now offers access to this extensive molecular profiling information through the blood by looking at the unique methylation signatures of specific tumor biomarkers. The company also announced the addition of a full suite of immunohistochemistry (IHC) testing to its portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted therapies.
TEM Stock Outperforms Industry & Benchmark
Year to date, Tempus AI shares have surged 91%, outperforming the industry’s 24.1% growth and the S&P 500 composite’s 8.2% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.84X compared to the industry average of 5.90X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's projected loss per share has improved 2.8% for 2025 and 12% for 2026.
Image: Bigstock
Tempus AI Taps Growing ICI Market With New xM Assay
Key Takeaways
Tempus AI, Inc. (TEM - Free Report) recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus AI’s growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). This innovative offering marks a significant advancement in the precision oncology space, where real-time response monitoring is essential for optimizing cancer treatment.
The rising prevalence of cancers such as lung, breast, bladder, and cervical cancers, as well as melanomas and hodgkin lymphoma, has driven the adoption of immune checkpoint inhibitor therapies as a key component of modern cancer treatment. Per a Grand View Research analysis, the global immune checkpoint inhibitors market size is projected to reach $154.25 billion by 2030, at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2030.
xM for TRM is designed to quantify changes in circulating tumor DNA (ctDNA) longitudinally from a blood sample, enabling early molecular response assessment in patients with advanced cancers receiving ICI alone or combination therapies. xM for TRM leverages a unique multi-parametric algorithm, integrating copy number variations (CNVs), along with somatic and germline variant allele frequencies (“VAFs”), for a comprehensive and robust estimation of circulating tumor fraction.
Recent Development by TEM’s Competitors
In March, Exact Sciences (EXAS - Free Report) launched the Cologuard Plus test, the company’s next-generation colon cancer screening test. The Cologuard Plus test detects cancers and precancerous polyps with even greater sensitivity than the Cologuard test while reducing false positives by nearly 40%. In April, it launched the Oncodetect test, its molecular residual disease and recurrence monitoring test. Furthermore, the company is on track for the launch of Cancerguard EX, a laboratory-developed multi-cancer screening test, in the second half of 2025.
Guardant Health (GH - Free Report) has enhanced its Guardant360 Liquid test by launching nearly a dozen new applications built on its Guardant Infinity multiomic platform and AI engine. Comprehensive biomarker testing through immunohistochemistry (using tumor tissue) has been the standard of care in oncology. The Guardant360 Liquid test now offers access to this extensive molecular profiling information through the blood by looking at the unique methylation signatures of specific tumor biomarkers. The company also announced the addition of a full suite of immunohistochemistry (IHC) testing to its portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted therapies.
TEM Stock Outperforms Industry & Benchmark
Year to date, Tempus AI shares have surged 91%, outperforming the industry’s 24.1% growth and the S&P 500 composite’s 8.2% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.84X compared to the industry average of 5.90X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's projected loss per share has improved 2.8% for 2025 and 12% for 2026.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.